G astroesophageal reflux disease (GERD) is a serious condition because of the potential for chronic symptoms and complications, and its association with Barrett's esophagus and esophageal adenocarcinoma. 1 Fundamental to the disease process is an incompetent lower esophageal sphincter (LES) that allows abnormal reflux of gastric content into the esophagus. The gastric refluxate, which contains varying concentrations of acid, pepsin, enzymes, and other content, influences symptoms and mucosal damage by its type, acidity, volume, and exposure time via contact with esophageal surfaces. 2, 3 Acid-suppression therapy, in the form of proton pump inhibitors (PPIs), is the primary treatment for GERD. This drug class has been shown to be most effective for acid-related symptoms, such as heartburn and esophagitis, and less effective for regurgitation because PPI therapy does not address the underlying incompetency of the LES. 4 Acid-suppression therapy may change the composition of the refluxate, particularly its acidity, but it does not prevent abnormal reflux, leaving patients at risk for ongoing symptoms and progression of disease. 5 Esophagogastric fundoplication addresses the incompetent LES by mobilizing the gastric fundus to form a fundic wrap around the distal esophagus, resulting in permanent loss of normal gastric fundic anatomy, and involves dissection of the phreno-esophageal ligaments, which secure the esophagus to the diaphragm. 6 Nissen fundoplication has long been associated with effective reflux control, albeit at the expense of inducing new side effects, such as gas-bloat, flatulence, and inability to vomit. 7, 8 The placement of a magnetic sphincter augmentation device (LINX Reflux Management System; Torax Medical, Inc, Shoreview, MN) is the only antireflux procedure that mechanically restores competency to the reflux barrier without using the gastric fundus. 9,10 Based on 2-year results, the Food and Drug Administration (FDA) granted approval of the magnetic device for GERD in 2012. 11, 12 The final results of the 5-year magnetic sphincter augmentation study are reported.
Methods

Study Design
This was a prospective, multicenter, single-arm study with predefined success criteria. Each patient served as his or her own control, with the treatment effect assessed by comparing follow-up assessments with baseline. This study purposely was designed to provide valid scientific evidence to support FDA approval. Both objective and subjective evaluations were performed to evaluate the treatment effect. The authors had access to the study data at all times and the co-authors reviewed and approved all manuscript drafts and the final manuscript.
Patients
A total of 14 centers (13 in the United States and 1 in The Netherlands) enrolled patients. Eligible patients were 18 to 75 years old, had at least a 6-month history of GERD, a partial response to daily PPIs, and pathologic esophageal acid exposure confirmed by pH monitoring. Exclusion criteria included evidence of hiatal hernia greater than 3 cm, esophagitis grade C or D according to the Los Angeles classification, body mass index higher than 35, Barrett's esophagus, or motility disorder. In the study, the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) questionnaire was administered both with and without PPIs before treatment to assess changes in the total score. Per the protocol, a subject was considered a partial PPI responder if the following inclusion criterion were met: subjects with persistent reflux symptoms and partial symptomatic improvement on PPI therapy shown by a GERD-HRQL score of 10 or less on PPI and 15 or higher off PPI, or subjects with a 6-point or more improvement when comparing their GERD-HRQL score on PPI and off PPI.
Study Procedures
The baseline screening, surgical technique, and follow-up evaluation were reported previously. 12 The magnetic device was placed by foregut surgeons using standard laparoscopic tools and techniques. A crural repair was performed at the surgeon's discretion; cruroplasty was performed in 34% of patients. The device uses magnetic attraction to create resistance to an abnormal opening of the LES to prevent reflux events, but still allows normal LES opening for swallowing food, belching, and vomiting ( Figure 1 ).
Postapproval Evaluations
The efficacy end points after FDA approval were the same as before approval, with the exception that esophageal pH monitoring was performed after the procedure only at 1 year and these results were reported previously. 12 Quality of life was measured with the GERD-HRQL questionnaire. 13 Total scores range from 0 to 50, with higher scores indicating worse symptoms. For those patients who had resumed PPIs, the dose and frequency were recorded, and the PPI was stopped for at least 7 days before completing the questionnaires. Postapproval efficacy end points included the following: the number of patients achieving at least a 50% reduction in the GERD-HRQL score as compared with the baseline score without PPIs; and a reduction of at least 50% in the dose of PPIs compared with baseline. The efficacy end point was achieved if met by at least 60% of patients.
Additional side effects and reflux-related symptoms were actively queried before and after treatment with the Foregut Symptoms Questionnaire. 14 The 5-year evaluation included endoscopy to evaluate the presence of esophagitis, Barrett's esophagus, or device erosion. Chest radiography was used to confirm the device remained at the gastroesophageal junction.
Statistical Analysis
Postapproval analyses were performed on GERD-HRQL scores and use of PPIs per the predefined success criteria. Safety was monitored throughout the postapproval period as the rate and type of serious adverse events related to the device or implant procedure.
Continuous variables were summarized with the use of standard descriptive statistics (eg, mean, standard deviation, median, range). Categoric variables were summarized via frequency distributions. The 2-tailed, paired Student t test or the Wilcoxon signed rank test were used to compare before and after implant values for continuous outcomes and the McNemar test was used to assess changes in binary outcomes from before to after implant. Differences were considered significant at a P value of less than .05.
Results
Patient Characteristics
The study population consisted of 100 patients, 52% males and 48% females. The median age at the time of implant was 53 years (range, 18-75 y), with a median body mass index of 28 (range, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . The median duration of reflux symptoms was 10 years (range, 1-40 y). The median duration of treatment with PPIs was 5 years (range, <1 to 20 y). Each patient had confirmed pathologic esophageal acid exposure without PPIs (median percentage of time pH was less than 4 was 10.9%; range, 4.8%-25.4%). Eighty-five patients had a follow-up evaluation at 5 years; a few analyses were performed on 84 patients if data were incomplete, and 82 patients completed endoscopy at the 5-year mark. A consolidated standards for the reporting of trials diagram is provided in the Supplementary Appendix.
Efficacy Success Criteria at 5 Years
A 50% or greater reduction in GERD-HRQL score was achieved in 83% of patients at 5 years (70 of 84; 95% confidence interval, 73-91) ( Figure 2 ). A reduction of 50% or more in the average daily dose of PPIs occurred in 89.4% of patients at 5 years (76 of 85 patients; 95% confidence interval, 81-95) ( Figure 2 ). Per the predefined criteria, long-term efficacy was maintained.
Additional Reflux Analyses
Additional analyses, using the GERD-HRQL and Foregut Symptoms Questionnaire, were performed (84 patients were available for these analyses). Patients with moderate or severe heartburn had a decrease from 89% to 11.9%, and moderate or severe regurgitation decreased from 57% to 1.2% without use of PPIs at baseline and 5 years. Patient dissatisfaction before treatment was 95%, and decreased to 7.1% at 5 years ( Figure 3 ) (P < .001 for all comparisons with baseline).
Daily use of PPIs was 100% at baseline and decreased to 15.3% at 5 years. At 5 years, 75.3% of patients reported complete cessation of PPIs, and 9.4% reported PPI use only as needed. Thus, 84.7% were either completely off PPIs or reported use as needed at 5 years after surgery. Patients who required double-dose PPIs decreased from 36% at baseline to 2.4% at 5 years. Of the patients reporting dissatisfaction at 5 years, all but 1 (5 of 6) reported daily use of PPIs (Figure 4 ).
Comparing the total GERD-HRQL scores at 5 years without PPIs with scores with and without PPIs at baseline, the median total score at baseline was 27 without PPIs and 11 with PPIs, and the score decreased to 4 after surgery at 5 years (P < .001 for all comparisons with baseline) ( Figure 5 ). The median GERD-HRQL score for patients reporting any use of PPIs within 30 days of the 5-year follow-up period was 7 (after PPIs were discontinued for at least 1 week) and 2.5 for patients reporting no PPIs.
Esophagitis
Healing of esophagitis occurred in 76.5% (26 of 34) of patients evaluated at 5 years. Among the 8 patients with ongoing esophagitis, 6 patients had grade A and the other patients had grade B. Of the patients without esophagitis at baseline and evaluated at 5 years, 90% (43 of 48) continued to have no esophagitis. Among the 5 patients with de novo esophagitis, 4 patients had grade A and 1 patient had grade B. No patients developed Barrett's esophagus during the study.
Other Symptoms
Other symptoms commonly associated with antireflux surgery or reflux disease were minimal at 5 years compared with baseline ( Figure 6 ). All patients reported the ability to belch and vomit (if needed). Patients reporting bothersome swallowing was 5% at baseline and 6% at 5 years (P ¼ .739); symptoms of bloating/gas decreased from 52% at baseline to 8.3% at 5 years (P < .001). In addition, per the Foregut Symptom Questionnaire, patients reported less diarrhea (P ¼ .103), For quality of life, 83% achieved at least a 50% reduction in total GERD-HRQL score, with a lower-bound confidence interval of 73%. For reduction in proton pump inhibitor use, 89% achieved at least a 50% reduction in daily proton pump inhibitor use, with a lower-bound confidence interval of 81%. constipation (P ¼ .008), and nausea/vomiting (P ¼ .003) after treatment.
Safety
Since the last report at 3 years, no new safety concerns have emerged. 12 No device erosions, migrations, or malfunctions occurred in this study. Device removal occurred in 7 patients. In 4 of the patients, the device was removed at 21, 31, 93, and 1807 days after implantation because of persistent dysphagia, with resolution after removal. One patient had the device removed at 357 days owing to intermittent vomiting of unknown cause starting 3 months after placement, without relief after removal. The device was removed in 1 patient at 489 days because of persistent reflux symptoms and another device was removed at 1062 days because of persistent chest pain. Three patients subsequently underwent uneventful Nissen fundoplication after device removal.
Discussion
Persistent symptoms of heartburn and regurgitation warrant careful monitoring. Ignoring persistent reflux symptoms can lead to severe complications, such as esophageal strictures, Barrett's esophagus, and esophageal adenocarcinoma. 15 Consideration of other treatments may become necessary when medical therapy fails to control symptoms. In the current study, we enrolled patients who had been treated with PPIs for several years, who still did not obtain adequate reflux control. These patients sought surgical treatment, but elected to forego conventional fundoplication surgery, instead opting for esophageal sphincter augmentation using a magnetic device.
The majority of patients reported moderate or severe regurgitation at baseline in this study, symptoms for which PPIs largely are ineffective. 16, 17 Five years after magnetic sphincter device placement, moderate or severe regurgitation was eliminated in all but 1 of 57 patients. Without a procedure to correct an incompetent LES, it is unlikely that continued medical therapy would have improved these reflux symptoms, and the severity and frequency of the symptoms may have worsened. 18 In this study, side effects commonly associated with Nissen fundoplication largely were absent, consistent with other studies of the magnetic device. 12, [19] [20] [21] Louie et al 22 provided a rationale for the difference in sideeffect profile between the magnetic device and Nissen fundoplication: Nissen fundoplication reduces the total number of reflux episodes to less than what is considered normal, creating a "super-normal" sphincter that is highly effective at preventing reflux but to the point of preventing or decreasing venting of ingested air under normal circumstances. The inability to vent (ie, belch) and the reduced number of normal reflux episodes after Nissen fundoplication likely is associated with the side effects of bloating and flatulence. In contrast, the magnetic device results in more normal sphincter function. 22 The rate of laparoscopic device removal was 7% over a 5-year period and has been reported to be 3% in another study spanning 6 years of clinical experience. 21 These rates are less than the expected range for reoperation after laparoscopic fundoplication at 5 years. [23] [24] [25] [26] Reoperation rates for transoral fundoplication at 5 years are not available, but revision rates from shorter-term experiences have been reported to be between 11.5% and 52.6%. [27] [28] [29] [30] Importantly, all device removals in our study were performed electively with no procedurerelated complications, whereas reoperations after laparoscopic fundoplication often are associated with a higher rate of complications and morbidity. 31, 32 It appears that the severity of complications and risks associated with reoperation are less after magnetic sphincter augmentation than fundoplication. [33] [34] [35] Importantly, in this long-term study, no device erosions occurred. Other investigators 36 have reported an erosion rate of much less than 1%. The magnetic sphincter augmentation device was engineered specifically to minimize the risk of device erosion and overcome the problems of previous barrier devices. 37 The device provides sphincter augmentation by means of Figure 5 . Median total GERD-HRQL score. Median score from the GERD-HRQL measures at baseline without and with proton pump inhibitors, as compared with magnetic sphincter augmentation at 5 years. Higher scores indicate worse symptoms. There was significant improvement in the median score at 5 years, as compared with baseline, both without and with proton pump inhibitor use. dynamic, expansible magnetic forces, not bulk or compression. The device mirrors physiologic LES opening and closing in that it opens for food bolus transport (its opening area can increase more than the esophagus), and shows progressively less force the larger the bolus, as opposed to alternative rigid designs that use fixed diameters around the esophagus, allowing for little or no device distention. Long-term clinical experience confirms that the magnetic sphincter augmentation device design is not prone to cause esophageal wall erosions.
This study had some limitations. Per the FDAapproved protocol, esophageal pH testing and manometry were not performed beyond 1 year. Manometry data have been reported previously with no significant change in any manometric parameter. 12 Esophageal pH results at 1 year showed that the majority of the patients had normalization of esophageal acid exposure along with symptomatic improvement and discontinuation of PPIs. 12 Longer-term pH data would have strengthened our conclusions. In addition, the study did not have a comparison group. Instead the trial design allowed for assessment of long-term outcomes via rigorous followup compliance, which is important in a chronic disease state such as GERD. This study describes a long and complete multicenter follow-up evaluation of a novel GERD-device cohort, used predefined success criteria, and purposely was designed to provide valid scientific evidence to support FDA approval. Both objective (pH and manometry) and subjective evaluations were performed to evaluate the treatment effect. Consistent with clinical practice, the extended 5-year follow-up period focused on both maintenance and durability of symptom improvement, and discontinuation of PPI therapy, and the objective clinical evidence of reduction in esophageal acid exposure was corroborated by the subjective findings. The consistent results of this 5-year study provide confidence that when used as indicated, there is a high probability that magnetic sphincter augmentation will improve the antireflux barrier and provide durable clinical benefits.
In conclusion, this study showed that patients with chronic GERD and failed long-term PPI therapy benefited from surgical intervention with magnetic sphincter augmentation. Long-term safety and efficacy have been validated for this procedure. It should be considered a first-line therapy for patients and physicians seeking a fundic-sparing antireflux procedure.
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